May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Serological Tumormarkers, Melanoma Inhibitory Activity" (MIA) and Osteopontin (OPN) for Metastatic Uveal Melanoma: Results of a Pilot Study
Author Affiliations & Notes
  • I. Reiniger
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • A. Wolf
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • U. Welge-Lüssen
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Rü. Hein
    Department of Dermatology, Technical University, Munich, Germany
  • A. Mueller
    Department of Ophthalmology, Clinic Augsburg, Augsburg, Germany
  • A. Kampik
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • U. Schaller
    Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Footnotes
    Commercial Relationships I. Reiniger, None; A. Wolf, None; U. Welge-Lüssen, None; R. Hein, None; A. Mueller, None; A. Kampik, None; U. Schaller, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4788. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Reiniger, A. Wolf, U. Welge-Lüssen, Rü. Hein, A. Mueller, A. Kampik, U. Schaller; Serological Tumormarkers, Melanoma Inhibitory Activity" (MIA) and Osteopontin (OPN) for Metastatic Uveal Melanoma: Results of a Pilot Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4788.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Aim of this pilot study was to evaluate Osteopontin (OPN) as a potential new marker in comparison to the protein ,,Melanoma Inhibitory Activity" (MIA), a previously described sensitive and specific serological tumor marker for screening and detection of metastatic uveal melanoma.

Methods:: 28 plasma samples of 27 patients with uveal melanoma were analysed and the OPN levels quantified (ELISA). Eight of these patients showed liver metastasis. The OPN levels were compared to the MIA levels from our Database, which had been obtained from the same patients previously.

Results:: The median plasma concentration of OPN in melanoma patients without metastasis was 46.78 ng/ml. The eight patients with proven metastatic disease showed OPN levels of 170.72 ng/ml (p < 0,001). As for OPN, the difference in MIA serum levels between patients without (5.64 ng/ml) and patients with (14.62 ng/ml; p < 0,001) metastatic disease was statistically significant.

Conclusions:: After developing metastatic disease statistically significant elevation of MIA and OPN serological levels could be demonstrated. Both the protein MIA and the OPN seem to be promising tumor markers for monitoring patients with uveal melanoma.

Keywords: uvea • melanoma • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×